Profile data is unavailable for this security.
About the company
Arch Biopartners Inc. is a therapeutic biotech company developing novel drugs for acute and chronic kidney diseases. The Company is advancing an integrated pipeline that includes new treatments targeting inflammation and toxin-induced kidney injury. Its programs include a pre-clinical chronic kidney disease platform targeting interleukin-32 (IL-32), LSALT peptide, a dipeptidase-1 (DPEP1) inhibitor in Phase II for preventing cardiac surgery-associated acute kidney injury, and cilastatin, a repurposed drug in Phase II for preventing toxin-induced kidney damage. These assets represent distinct, mechanism-based approaches to treating and preventing common causes of kidney damage. Together, they target serious unmet needs in kidney care across both chronic and acute indications, affecting millions of patients worldwide. Its LSALT Peptide and cilastatin, are being developed to target kidney injury caused by inflammation or toxins respectively, which are both significant unmet medical needs.
- Revenue in CAD (TTM)275.95k
- Net income in CAD-1.55m
- Incorporated2003
- Employees--
- LocationArch Biopartners Inc545 King St W.TORONTO M5X 1A1CanadaCAN
- Phone+1 (647) 428-7031
- Fax+1 (647) 351-3565
- Websitehttps://archbiopartners.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Decibel Cannabis Company Inc | 109.31m | 12.32m | 51.46m | -- | 3.41 | 0.8166 | 2.65 | 0.4708 | 0.0264 | 0.025 | 0.198 | 0.1102 | 0.795 | 2.15 | 6.51 | -- | 8.96 | -0.0401 | 13.94 | -0.0595 | 21.98 | 20.03 | 11.27 | -0.0688 | 0.6086 | -5.57 | 0.4186 | -- | -12.89 | 71.51 | 810.61 | -- | -4.74 | -- |
| Arch Biopartners Inc | 275.95k | -1.55m | 52.39m | -- | -- | -- | -- | 189.87 | -0.0237 | -0.0237 | 0.0042 | -0.0587 | 0.5306 | -- | 0.7616 | -- | -298.56 | -195.50 | -- | -- | -- | -- | -562.69 | -123.23 | -- | -3.99 | -- | -- | -87.00 | 32.37 | 60.39 | -- | -- | -- |
| LSL Pharma Group Inc | 26.80m | 2.78m | 65.30m | -- | 21.66 | 2.48 | 12.97 | 2.44 | 0.024 | 0.024 | 0.2307 | 0.2094 | 0.5462 | 1.98 | 5.78 | -- | 5.65 | -- | 7.29 | -- | 29.73 | -- | 10.35 | -- | 0.5366 | 0.6521 | 0.5325 | -- | 76.98 | -- | 139.15 | -- | -- | -- |
| Eastwood Bio-Medical Canada Inc | 594.57k | -411.84k | 68.89m | -- | -- | -- | -- | 115.86 | -0.006 | -0.006 | 0.0086 | -0.0225 | 2.17 | -- | 26.00 | -- | -150.26 | -71.29 | -- | -- | 63.91 | 56.40 | -69.27 | -57.09 | -- | -31.24 | -- | -- | -19.11 | -11.50 | 16.60 | -- | -- | -- |
